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background:Unintendedpregnancyand sexually transmitted infections (STIs) are themajor negative consequencesof unsafe sex.Both are
common and have long-term social and health consequences. Barrier methods of contraception can prevent both, but unfortunately they are
much less effective than the more modern methods at pregnancy prevention. Modern effective contraceptives, however, do not protect
against STIs and some may increase the risk of acquisition of infection. This comprehensive review discusses the magnitude of burden of repro-
ductive ill-health, focussing on data from the European region, and explores the relationship between contraceptive use and STIs.
methods: Searcheswere performed by using Medline, Popline, EMBASE, Cochrane Library and the Social Sciences Citation Index databases
for relevant English language publications from 1995 to 2012. Summaries were discussed by the European Society of Human Reproduction and
Embryology (ESHRE) Workshop Group.
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results: An understanding of patterns of sexual behaviour helps to understand the epidemiology of unintended pregnancy and STIs and gives
pointers towards their prevention, but survey methodologies differ and results are hard to compare. Contraceptive prevalence and method mix
vary widely between countries, and the use of the dual method of protection is very infrequent. Abortion rates have fallen in many European
countries, particularly Eastern Europe, and contraceptive prevalence increased but unsafe abortion still accounts for 11% of maternal mortality
in Eastern Europe. STIs are commonbut reporting systems areoften rudimentary or non-existent and robust data are scarce. Providers still worry
about the effect of intrauterine contraception on reproductive tract infections despite reassuring evidence to the contrary. New data on HIV ac-
quisition and hormonal contraception are causing concern in settings whereHIV infection is common. New developments in multipurpose tech-
nologies aimed atproducing a single device/drug,which prevents infection and pregnancy simultaneously, are in early stages.While thebeneﬁts of
national screening programmes for STIs remain uncertain, human papilloma virus (HPV) vaccination is clearly reducing HPV infection rates and
gives hope for the public health beneﬁts of other STI vaccines.
conclusions: The consequences of unsafe sex—unintended pregnancy and STI—continue to present major public health problems
worldwide even in countries where the prevalence of use of modern contraception is high. Robust systems for routine data collection are
sorely needed in most countries and systematic attempts to compare patterns of sexual behaviour across men and women of all ages would
be welcome.
Key words: STIs / sexual behaviour / unintended pregnancy / contraception / dual protection
Introduction
At the start of the21st century,WHOidentiﬁedunsafe sexas the second
most important risk factor for disease, disability or death in the poorest
communities and the ninth in developed countries (Ezzati et al., 2002).
Unintended pregnancy and sexually transmitted infections (STIs) are
the major negative consequences of unsafe sex. Both have signiﬁcant
long-term social and health consequences even in developed countries.
Many unintended pregnancies end in induced abortion. In countries
where abortion is legal and generally safe, it is nonetheless distressing
for all concerned: where abortion is unsafe it is a signiﬁcant cause of ma-
ternal mortality and morbidity. If pregnancy is continued, unintended
childbirth is often associated with single motherhood and with
reduced life chances for both the mother and her child. STIs increase
the risk of infertility, ectopic pregnancy, cervical cancer and, in the case
of HIV/AIDS, death (WHO, 2012b). These outcomes of unsafe sex
are not independent of one another; womenwho are at risk of unintend-
ed pregnancymay also be at risk of acquiring a STI—and vice versa. Both
can beprevented.Unfortunately,methodswhich prevent STIs (male and
female condoms) are not as effective at preventing pregnancy as hormo-
nal and intrauterine contraception, which provide little if any protection
against STIs and may in fact be associated with an increased risk of
the acquisition or transmission of some infections. All specialists con-
cerned with the sexual and reproductive health of men and women
should have a concern about STIs and unintended pregnancy and their
prevention, both from an individual patient’s perspective and from a
public health one.
This paper explores the relationship between contraceptive use and
STIs, and the effects of speciﬁc methods of contraception on the risks
of acquisition or transmission of STIs and their serious consequences.
Much of the literature on these two topics comes from the USA or
from developing countries and is referred to in the reviewwhen relevant
or when European data are unavailable. The review draws on European
data when available to illustrate the magnitude of the burden on health
and to highlight the need for better measurement of both STIs and unin-
tended pregnancy in this part of the world. The paper makes some sug-
gestions for strategies to prevent both STIs and unintended pregnancy.
Methods
For this general review, searches for relevant English language publications
from1995to2012wereperformedby individual participants in theworkshop
using Medline, Popline, EMBASE, Cochrane Library and the Social Sciences
Citation Index databases. Subject summaries were presented to the Euro-
pean Society of Human Reproduction and Embryology (ESHRE) Workshop
Group, where omissions or disagreements were resolved by discussion.
Sexual behaviour
Since they are important in determining fertility and transmission of STIs,
sexual behaviour contributes substantially to the burden of disease.Data
on sexual behaviour come from surveys which use different methodolo-
gies, but all relyon self-reporting.More surveys, andmore standardmea-
sures, are available for developing countries for which data are collected
through repeated Demographic and Health Surveys (Wellings et al.,
2006). Data are much harder to ﬁnd for developed or middle-income
countries, and where they are available they are difﬁcult to compare.
Questions common to almost all sexual behaviour surveys—and allow-
ing at least somecomparison—relate to age at ﬁrst sexand contraceptive
use. Much of the interest in adolescent sexual activity relates to the rela-
tively high incidence of STIs and unintendedpregnancy among teenagers,
the issues of morality which this raises in many countries and the need to
improve patterns of use of condoms and other methods of contracep-
tion. One study which analysed data from surveys of sexual behaviour
from 59 countries around the world reported a comparison between
ﬁve European countries: the UK, France, Italy, Norway and Switzerland
(Wellings et al., 2006). This showed somedifferences between countries
in the median age of ﬁrst sex and in the percentage of boys and girls
reporting having sex before the age of 15 (Table I; Wellings et al.,
2006).Data for Europeas awhole are limited to theWHOmulti-country
Health andBehaviour in SchoolAgeChildren (HBSC) survey undertaken
among 15-year-old students. That survey offers a unique opportunity to
explore regional patterns of early sexuality in Europe (Currie et al., 2004,
2012). The proportion of sexually experienced girls has held relatively
constant over the last decade (24% ever had sexual intercourse at
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age 15), with ﬁgures ranging from 17% in Central and Eastern Europe to
36% in Northern Europe.
Epidemiology of contraceptive
use, unintended pregnancy and
STIs
Contraceptive use
Globally, the total fertility rate (TFR) fell by 29% between 1994 and 2012
and the contraceptive prevalence rate (CPR) among women 15–49
years who are married or in union increased from 58.4 to 63.6%, a rise
of 10% (United Nations, 2012). Trends in contraceptive behaviours
in Europe reported from 1997 to 2007 show signiﬁcant progress in the
use of modernmethods in Eastern andNorthern Europe, but a slight re-
duction in Southern and Western Europe (United Nations, 2010). The
CPR across the European regions varies from 64% in Southern to 80%
inNorthern Europe (Table II;UnitedNations, 2010). These regional pat-
terns hide big differences between individual countries within the same
region. So, for example, use of the oral contraceptive pill (OC) in the
Eastern European region varies from 3.4% in Poland to 39.4% in
Hungary; while in Western Europe intrauterine device (IUD) use
ranges from 5.3% in Germany to 22.7% in France; and in Southern
Europe 3.5% of couples in Portugal rely on withdrawal while in Albania
withdrawal accounts for over 57.9% of contraception.
Although the data are available for a limited number of countries only,
unmet need for contraception varies substantially, from ,4% in
Western European countries to 10% or more in Southern and Eastern
Europe. Concurrently, the proportion of women using very effective
methods (hormonal, IUD and sterilization) increases from 29% in
Southern Europe to 64% in Western Europe (United Nations, 2010).
The use of condoms at last intercourse has increased from 70 to 78%
among young girls between 2000 and 2010 and has remained stable
among boys (80 and 81%). Among adolescents condom use varies
little by region, while the use of the pill varies signiﬁcantly from an
average of 12% in Eastern Europe to 45% in Western Europe (Currie
et al., 2012). Condom use tends to be lower in countries with high use
of oral contraception (Fig. 1).
Unintended pregnancy
Unintended pregnancy rates—which include births as well as induced
abortions—represent an important indicatorof thequalityof family plan-
ning policies and programmes. Globally, the absolute number of abor-
tions declined from 45.6 million in 1995 to 43.8 million in 2008 (Sedgh
et al., 2012). Unfortunately, information on births is mostly unavailable
and, where data do exist, the deﬁnition of ‘unintended’ varies. In
France and UK, around one-third of births are reported as unintended,
most of which occur while women are using contraception (Bajos
et al., 2003; Lakha andGlasier, 2006). A simple, standardmeasure of un-
intended pregnancy has been validated for use in the UK and could be
adapted for other national surveys to allow comparison of rates of unin-
tended births (Barrett et al., 2004). Abortion rates are often used as a
surrogatemeasure of unintended pregnancy. The availability of abortion
varies across EuropeRegion: almost all countries permit abortion to save
the mother’s life and 90% to preserve mental/physical health; 88% of
countries permit abortion for serious fetal anomaly, or if the pregnancy
results from rape or incest. Nearly 80% allow abortion for ‘social or eco-
nomic’ reasons, and over 70% offer abortion on request. Abortion is
illegal on any grounds in Malta and Andorra, and is severely restricted
in Poland and Ireland (WHO Regional Ofﬁce for Europe, 2014). Even
when abortion laws are relatively liberal, there are huge variations in
reporting. In some countries with mandatory reporting and where
.............................................................................................................................................................................................
Table I Early sexual activity in ﬁve European countries (adapted fromWellings et al., 2006).
Country Median age ﬁrst
sex (women)
Median age ﬁrst
sex (men)
% sex before age
15 (women)
% sex before
age 15 (men)
UK 17.5 16.5 6.9 12.5
France 18.5 17.5 5.9 7.2
Italy 18.5 17.5 2.8 4.0
Norway 17.5 18.5 9.6 5.5
Switzerland 18.5 18.5 3.4 6.8
.............................................................................................................................................................................................
Table II Use of contraception (%) including method mix among European regions (United Nations, 2010).
European
region (TFR
2012)
Any
method
Any
modern
method
Female
sterilization
Male
sterilization
Pill IUD Condom Fertility
awareness
Withdrawal
Eastern (1.41) 74.9 54.3 0.9 0.2 11.6 16.3 22.2 9.1 10.4
Northern (1.86) 80.1 77.2 6.1 12.3 22.0 11.9 20.9 1.2 1.5
Southern (1.43) 63.8 46.3 4.6 2.4 16.1 5.7 17.6 2.5 14.4
Western (1.64) 71.9 68.6 4.6 1.7 46.5 11.4 4.8 2.1 0.8
TFR, total fertility rate; IUD, intrauterine device.
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most abortions are undertaken in a public hospital setting (e.g. UK and
Sweden), abortion statistics are robust, while in others abortion report-
ing is poor and the resulting statistics unreliable. Some countries in
Western Europe have the lowest abortion rate in the world (12/1000
women of childbearing age). Conversely, Eastern Europe (Belarus, Bul-
garia, the Czech Republic, Hungary, Poland, Moldova, Romania, the
Russian Federation, Slovakia and Ukraine) has the highest estimated
abortion rate in the world. In 2003, there were 103 abortions for
every 100 live births. There has nonetheless been a dramatic fall in abor-
tion rates in Eastern Europe—from an estimated 90 per 1000women of
reproductive age in 1995 to 44 in 2004 (Fig. 2). The decline coincided
withmarked increases in contraceptive use in the region.Adisconcerting
featureof these disparities remains the occurrenceof unsafe abortions in
Eastern Europe, responsible for 11% of maternal mortality in the region.
Sexually transmitted infections
The number of annual incident cases of STIs appears to have increased
worldwideby40%since1995 (WHO,2012a). This is likely tobe a reﬂec-
tion of increased diagnosis and reporting. STIs pose amajor public health
burden inEuropeas theydoworldwide.TheEuropeanCentre forDisease
Prevention and Control (ECDC) published a surveillance report on STI
epidemiology for the period 2009–2010 (European Centre for Disease
Prevention and Control, 2011) which at least gives some idea of the size
of the problem and trends. European statistics for the six major STIs are
reported in Table III. However, few countries outside North-West
Europe have accurate reporting systems for STI. National surveillance
systems comprise a mix of voluntary, sentinel or selected laboratory
systems and often do not represent true national coverage.
Chlamydia trachomatis
Chlamydia trachomatis is the most frequently reported STI in Europe, but
since70% of cases are asymptomatic, the rate of 186/100 000 is likely
to be grossly underestimated. Reporting in Scandinavia (Sweden,
Norway, Denmark and Finland), the Netherlands and the UK accounts
for 95% of all cases of Chlamydia infection in Europe. The highest
conﬁrmed case rates were reported by Iceland (691 per 100 000),
Denmark (505 per 100 000), Norway (464 per 100 000) and Sweden
(386 per 100 000). Rates are highest in the 15- to 24-year age group
(75% of cases reported). Rates have continued to increase; a doubling
of the rate over 10 years reﬂects increased diagnosis and reporting, in-
cluding active case ﬁnding and in some places screening. Population-
based data on the prevalence of STIs are very rare. In a recent large,
randomBritish Surveyof SexualAttitudes andLifestyles (Natsal 3) involv-
ing over 15 000 men and women, urine from a sample of sexually active
participantswas tested for a range of STIs (Sonnenberg et al., 2013). Sixty
percent of 8047 eligible participants provided a urine sample. Chlamydia
prevalence was 1.5% in women and 1.1% in men, but 3.1% in women
aged 16–24 and 2.3% in men of that age group.
In Europe,Chlamydia infection has arguably attracted themost interest
in systematic screening and treatment programmes. A survey of Chla-
mydia prevention programmes in 29 European countries (Low, 2008)
found wide variations. Only two countries had national programmes,
while almost half reported no organized activity. Countries that have
embarked upon, or considered embarking upon national screening pro-
grammes for Chlamydia infection, face a large amount ofmissing data. Al-
though all agree that C. trachomatis is globally the predominant curable
STI, its true incidence and prevalence are, oddly enough, far from clear
(Land et al., 2010). In women, C. trachomatis is the most frequently
involved causative agent of pelvic inﬂammatory disease (PID), and as
such the cause of subsequent tubal subfertility and ectopic pregnancy.
Research into the natural history of the disease is severely hampered
by the fact that most Chlamydia infections remain asymptomatic
and thereby escape the attention of the clinician. Colonization of
the cervix by C. trachomatis may remain unrecognized and does not
always lead to serious consequences (Land et al., 2010). Moreover,
spontaneous clearance rates of up to 50% have been documented in
untreated lower genital tract colonization by C. trachomatis (Morre´
et al., 2002). A positive Chlamydia antibody test is suggestive of a prior
C. trachomatis infection, but does not reﬂect the course of the disease.
If the Chlamydia infection is not cleared completely, a persistent infection
Figure 1 Reported condom and oral contraceptive use % by sexually experienced 15-year-old girls at last sex (from Currie et al., 2012, adapted).
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or re-infection may result inducing a chronic low-grade immune
response, destroying host cells and increasing the risk of tissue damage,
subsequent repair, scarring and adhesion formation. Land et al. (2010),
in an extensive literature review, estimated the risk of developing PID
after a lower genital tract C. trachomatis infection at between close to 0
and 30%, depending on the type of test used and the population
tested. They calculated the risk of PID processing to tubal subfertility
to bebetween10 and20% (Land et al., 2010). This impacts on the appro-
priateness of (annual) screening programmes for young sexually active
women, as proposed by many national guidelines (Low et al., 2009).
However, the recent decision reached in the Netherlands following a
large randomized trial of three rounds of Chlamydia screening—in
which screening uptakewas low—was not to roll out aChlamydia screen-
ing programme (Van den Broek et al., 2012).
Gonorrhoea
Reported rates and trends for gonorrhoeavarywidelyby country; 60%of
cases reported in 2010 were from the UK. More than 25% of cases oc-
curred among men who have sex with men (MSM) and 40% in people
aged ,25. In the Natsal 3 survey in Britain, the population prevalence
of gonorrhoeawas,0.1%prevalence in bothwomenandmen (Sonnen-
berg et al., 2013).
Syphilis
Syphilis was reported three timesmore frequently inmen than inwomen
(6.6 and 1.8 per 100 000 population, respectively) (EuropeanCentre for
Disease Prevention andControl, 2011). Fifty-ﬁve percent of all reported
cases (withdataon transmission)occurred inMSM.While in201017%of
all syphilis cases were reported in people aged 15–24, most cases were
reported among people over age 25. The fall in the rate of syphilis
(Table III) is mainly due to a previous 10 years. In contrast, signiﬁcant
increases have occurred in other countries. Congenital syphilis has
remained fairly constant [21 countries reported, 59 cases in 2012 (2.5
per 100 000 live births)] (European Centre for Disease Prevention and
Control, 2011); however, underreporting is likely to be substantial.
Hepatitis B
Hepatitis B ismost likely to affect people aged 25–34 years (33.2%of the
total number of cases). The incidence is similar for men (8.79 cases per
100 000) and women (7.42 cases per 100 000) (European Centre for
Disease Prevention and Control, 2011). Screening and immunization
programmes vary considerably between countries.
Hepatitis C
Similarly,Hepatitis B ismost likely to affect peoplebetweenage25 and34
(14.3% of cases: 21.5 per 100 000 in men and 10.3 per 100 000 in
women) (European Centre for Disease Prevention and Control,
2011). Surveillance systems, case deﬁnitions and testing programmes
vary across Europe making comparison between countries difﬁcult.
HIV/AIDS
Although the number of AIDS cases continues to decline—except in
some eastern European countries—HIV infection remains a major
public health concern. The total number of cases is constant (28 000
Figure 2 Induced abortions per 1000 women aged 15–49 years in the EU regions in the period 1970–2008 (Gissler et al., 2012).
........................................................................................
Table III STI reporting in Europe (EuropeanCentre for
Disease Prevention and Control, 2011).
Infection States
reporting
(n)
Total
cases
(n)
Rate/
100 000
Change
since 2006
(%)
Chlamydia 24 344 491 186 40
Gonorrhoea 28 31 983 10.4 5
Syphilis 29 17 884 4.4 50
Hepatitis B 27 14 745 3.4 –
Hepatitis C 26 26 678 6.9 –
HIV/AIDSa 28 27 116 5.7a –
aLikely to increase due to delayed reporting.
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per year), although the epidemiology varies considerably between coun-
tries (European Centre for Disease Prevention and Control/WHO Re-
gional Ofﬁce for Europe, 2012). Estonia has the highest incidence rates,
followed by Belgium and Latvia. Rates among MSM (39% of reported
infections) increasedby 34%between2004 and 2010,while heterosexu-
ally acquired infection (24% of cases) decreased by 25%. Infection in
injecting drug users (4%) declined by 40% during the same period, al-
though there were major outbreaks in Romania and Greece. In the
Natsal 3 survey in Britain, the population prevalence of HIV infection
was 0.1% in women and 0.2% in men (Sonnenberg et al., 2013).
Overall in Europe, there has been a 30% decrease in reported AIDS
cases, but increases in some Eastern countries. These surveillance data
suggest that the HIV epidemic is evolving with diverse transmission pat-
terns acrossEurope.Thenumberof people livingwithHIV is increasing as
treatment and survival improve. HIV remains highly concentrated in key
populations—MSM, people originating from sub-Saharan Africa and
injecting drug users. Data from CD4 counts suggest that 50% of diagno-
sesoccur late, reﬂectingpooraccess and/oruptakeof treatment inmany
countries.
Human papilloma virus
Data on infection rates with human papilloma virus (HPV) are not rou-
tinely reported—indeed, testing in most settings is not routine. More
than 150 types of HPV have been described about 40 of which can
infect the genital tract. About 70% of cases of cervical cancer are
caused by HPV 16 and HPV 18, and HPV types 6 and 11 are responsible
for90% of genital warts (European Centre forDisease Prevention and
Control, 2012). Data on cervical cancer are collected throughout
Europe, and each year there are some 33 000 cases and 15 000
deaths. HPV vaccines (Gardasilw and Cervarixw) are safe and highly ef-
fective in preventing persistent infection, cervical dysplasia and cancer,
but there are few data on efﬁcacy after 9 years.
Most countries in the European region (19/29) now have vaccination
programmes for adolescent girls. Ten countries have introduced
catch-up programmes for young women (European Centre for
Disease Prevention and Control, 2012). However, coverage rates are
lower than expected mainly due to expense and the need for three
doses over 6months. Uptake of all three doses in the UK, where vaccin-
ation programme started in 2008, is 87%. In the third Natsal survey in
Britain (undertaken between 2010 and 2012), prevalence of HPV
types 16 and 18 in women aged 18–20 years was lower than in
the second survey undertaken in 2000 (5.8 versus 11.3%, respectively)
(Sonnenberg et al., 2013). Recent trial data on quadrivalent vaccine
(Gardasilw) show that immunogenicity and efﬁcacy are also high in
boys. Despite the advantages of vaccinating boys (preventing anal
warts, oropharyngeal cancers and cervical cancer through herd immun-
ity), cost-effectiveness models do not favour inclusion of boys in HPV
vaccination programmes.
Other STIs
Dataon infection rates for other STIs, including trichomonas and herpes,
are not routinely reported.
Contraceptivemethods and STIs
The only contraceptive methods which prevent against both pregnancy
and STIs are barrier methods, speciﬁcally male and female condoms.
Below we present a summary of the evidence for prevention of both
pregnancy and STIs.
Barrier methods
Male condoms
Although themale condom is heavily promoted as themethod of choice
to reduce the risk of HIV and other STIs, it is considerably less effective
than so-called modern methods in the prevention of unintended preg-
nancy. Latex condoms are impermeable to sperm and to particles the
size of most pathogens associated with different STIs; condom failures
follow mainly from improper use, inconsistent use or lack of use,
rather than from condom breakage or slippage during vaginal sex. The
most robust evidence on condomeffectiveness concerns the prevention
of HIV infection, while information on effectiveness for the prevention of
STIs and pregnancy is less convincing. A systematic reviewof prospective
studiesonHIV-serodiscordant couples (mostly fromAfrica) showed that
the HIV incidence in couples who always used condoms was 1.14 (95%
CI 0.56–2.04) per 100 person-years compared with 5.75 (3.16–9.66)
per 100 person-years in those who never used condoms, an 80% re-
duction (Weller andDavis-Beaty, 2002). Based onUS data from couples
desiring pregnancy, about 85 of 100 couples would experience a preg-
nancy within 1 year of unprotected intercourse (Trussell, 2011). This
compares with about 18 pregnancies per 100 couples within 1 year of
typical use ofmale condoms for pregnancy prevention, also an80% re-
duction in risk. In contrast, about 2 in 100 couples using male condoms
correctly andconsistently inprospective studieswouldbecomepregnant
within 1 year—an approximate 97% reduction in risk during perfect
condom use (Trussell, 2011).
A review of condom effectiveness in 2000 concluded that there was
good epidemiological evidence that condoms reduced the risk of gonor-
rhoea inmen (National Institutes of Health, 2001). An updated review in
2004 concluded that condoms reduced the risk of genital HSV-2, syphilis
and chlamydial infection in men and women, trichomoniasis in women,
and accelerated the regression of cervical and penile HPV-associated
lesions and clearance of HPV infection by women (Holmes et al.,
2004). The basic concept of the male condom has not evolved over
the past 30 years. Non-latex condoms have not shown any advantages
over latex condoms, except for people with latex allergies, and
condom failure rates have been higher than latex condoms (Callahan
et al., 2000; Steiner et al., 2003). Recent innovations include polyureth-
ane strips to assist with correct and rapid application (http://www
.sensicondoms.com/) and a folded silicone condom (http://www
.origami.com/) currently awaiting regulatory approval.
Female condoms
In a prospective study of the Realityw polyurethane female condom
amongwomen from theUSAandLatinAmerica, the 6-monthpregnancy
ratewas15%(Farret al., 1994). Thecumulativeannual pregnancy rate for
the female condom was extrapolated to 21% under typical use condi-
tions and 5% under perfect use conditions (Trussell et al., 1994). To
date, there havebeen no convincing studies of the comparative effective-
ness of female and male condoms for pregnancy or STI prevention,
though a randomized study of male and female condom usewith a post-
coital swab for the presence of prostate-speciﬁc antigen showed that
some semen exposure occurred more frequently following female
thanmale condomuse (22 versus 15%). Therewas, however, little differ-
ence with regard to high levels of post-coital semen detected (5 versus
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4%) (Galvao et al., 2005). Innovation in female condoms has been driven
by the importance of reducing costs, facilitating insertion and increasing
acceptability (Beksinska et al., 2006; Schwartz et al., 2008). It is hoped
that availability of more than one product will increase availability and
choice of female condoms,which have the advantage of not requiring co-
operation of the male partner to be successfully used. However, female
condoms havemuch ground tomake up—in 2008, donor countries sup-
plied 18.2 million female condoms globally, compared with nearly 2.4
billion male condoms (Center for Health and Gender Equity, 2011).
Diaphragm
The diaphragm (Ortho-McNeil) used with Replens lubricant gel did not
reduce the incidence of HIV infection or STIs in a randomized study in
South Africa and Zimbabwe, though participants in the intervention
group used fewer (male) condoms than those in the control group
(Padian et al., 2007). Recent innovations with the diaphragm include a
device which can be loaded with spermicide or lubricant gel on both
the cervical and vaginal side (Ballagh et al., 2008), and the one-size ﬁts
all SILCS diaphragm (Coffey et al., 2008) now being commercialized in
Europe under the brand name CayaTM. Comparative effectiveness for
pregnancy or STI prevention of these new devices has not been estab-
lished and all provide for a lubricant or contraceptive gel to be used
with the device. While nonoxynol-9 spermicides can be used in settings
where women are at no or very limited risk of HIV infection, no safe and
effective spermicidal gel has been found that also reduces the risk of in-
fection with HIV or other STIs.
Spermicides
Spermicides are classiﬁed with fertility awareness methods as having the
lowestcontraceptiveeffectiveness andareestimated tohavea typical use
annual pregnancy rate of 28% and perfect use pregnancy rate of 18%
(Trussell, 2011). Since a double-blind trial showed that nonoxynol-9
spermicide resulted in an increased risk of HIV acquisition (Van
Damme et al., 2002), alternative contraceptive products that may
protect against HIV and other STIs have been sought. The acid buffering
agent BufferGel designed to maintain a vaginal pH of 4 even in the pres-
ence of semen was shown in animal models to prevent pregnancy and
some other STIs (Barnhart et al., 2007), but not HIV (Abdool Karim
et al., 2011).
Hormonal contraceptives
Oral hormonal contraceptives, transdermal patches and vaginal rings
when used perfectly have failure rates of 0.3% during the ﬁrst year of
use, while during typical use the failure rate is 8% (Trussell, 2011).
The relationship between hormonal contraception and STD acquisition
has been a topic of investigation for many years, though methodological
problems (e.g. cross-sectional design and failure to control for potential
confounding factors, such as sexual behaviour) have hampered many
studies. Hormonal contraceptives provide no protection against STIs.
Almost all the data come from studies of oral contraception since
patches and rings were developed relatively recently and the number
of users worldwide is extremely small. Consistently higher rates of cer-
vical infection with C. trachomatis have been found among users of
OCs (Cottingham and Hunter, 1992), but the relationship with other
STDs is unclear. It has long been suggested that the effect of hormones
on thickening cervical mucus may confer some protection against
upper genital tract infection and one study (among prostitutes in
Kenya) demonstrated that depot medroxyprogesterone acetate
(DMPA, depo proveraw) use was associated with a signiﬁcantly de-
creased risk of PID (Baeten et al., 2001). The overwhelming problem
of confounding in all observational studies of STI infection and use of
contraception is that condoms prevent against STIs including HIV, and
couples who use other contraceptives are less likely to use condoms
(Cates and Steiner, 2002). In case–control studies, contraceptive
methods that neither increase nor decrease risks of genital tract infection
are seen to artiﬁcially increase risks when condoms serve as the refer-
ence group (Hubacher et al., 2013). However, two serious conditions
possibly negatively associated with the use of hormonal contraception
are worthy of more detailed discussion—HIV infection and cervical
cancer.
Hormonal contraception and HIV/AIDS
Recent research, almost exclusively from Africa, has led to concerns
about a relationship between the use of hormonal contraception and
HIV infection. A number of animal studies have suggested biological
mechanisms by which different hormonal contraceptives may increase
the risk of HIV acquisition in women, HIV disease progression or
female-to-male HIV transmission (Huijbregts et al., 2013). In 2012, the
World Health Organization convened a technical consultation on hor-
monal contraception and HIV (WHO, 2012b) to review three public
health issues:
(i) Acquisition in HIV negative women.
Twenty studieswere identiﬁed, ofwhich eight cohort studies asses-
sing different hormonal methods met pre-deﬁnedminimum quality
criteria (Polis andCurtis, 2013). Collectively, the evidence does not
establish a clear causal relationship between use of injectable
progestogen-only contraceptives and HIV acquisition, but neither
does it exclude its possibility.
(ii) HIV disease progression.
Eleven studies were identiﬁedwhich investigated this association—
1 randomized clinical trial and 10observational cohort studies (Phil-
lips et al., 2013). Taken together, the evidence suggests thatwomen
livingwithAIDScanusehormonal contraceptionwithout it affecting
their risk of disease progression.
(iii) Female-to-male HIV transmission.
Only one cohort study was identiﬁed which provided direct
evidence about hormonal contraception and the risk of
female-to-male transmission of HIV (Polis et al., 2013). Overall,
there is insufﬁcient evidence to reach ﬁrm conclusions about
whether hormonal contraception facilitates female-to-male HIV
transmission.
Hormonal contraception, HPV infection and cervical cancer
Oncogenic HPV is the key risk factor for cervical cancer. The global
prevalence of HPV is 10–15%, with however appreciable variations
across various populations. HPV prevalence appears to be higher in
Eastern Europe, Latin America and sub-Saharan Africa than in other
areas of the world (Forman et al., 2012). In North America and
Europe, HPV 16 and 18 are the most frequent oncogenic types, while
HPV 31, 33, 45 and 58 are relatively common in Africa, Asia and Latin
America. Cervical cancer accounts for 85% of HPV-related cancers,
with 520 000 cases in 2012 (Forman et al., 2013). Most cases (and
deaths, i.e. 230 000 in 2012) occur in low- andmiddle-income countries.
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However, factors other than HPV inﬂuence cervical carcinogenesis,
including cigarette smoking and oral contraceptives (OCs) (La Vecchia
and Bosetti, 2003; Cibula et al., 2010; La Vecchia and Boccia, 2014).
The International Agency for Research on Cancer (IARC) conducted a
pooled analysis to analyse the combined effect and interactions between
HPV and OC on cervical cancer (Moreno et al., 2002). This included
1676 cervical cancer cases and 255 controls from two case–control
studies on in situ cancers and 8 studies on invasive cancer cervical. There
was no signiﬁcant excess risk for women reporting short-term OC use
(,5 years), but the relative risk (RR) was 2.8 for OC use 5–9 years and
4.0 for ≥10 years. HPV positivity was not correlated to OC use among
the controls, indicating thatOCs do not favour the acquisition ormainten-
ance of HPV infection, but appear to accelerate its progression to cervical
cancer. A meta-analysis of 28 studies reported increased cervical cancer
risks with longer duration OC use. The RRs were of 1.3–1.6 for 5–9
years and rose to 2.3–2.5 for ≥10 years (Smith et al., 2003). The RRs
were apparently of similar magnitude in users of progestogen-only inject-
able contraceptives, and were consistent across strata of HPV positivity.
The IARC–International Collaboration of Epidemiological Studies of
Cervical Cancer (Appleby et al., 2007) gave relevant information on dur-
ation and time since stopping OC. That study was based on a collabora-
tive re-analysis of data from 16 573 women with cervical cancer and
35 509 controls without cervical abnormalities. Allowance was made
for several relevant covariates, such as age, parity, smoking, age at ﬁrst
intercourse, number of sexual partners and history of screening. The
RR was 1.9 (95% CI 1.7–2.1) for current long-term (≥5 years) OC
users, but there was no appreciable association for shorter use. The
RR, however, declined after stopping use. Consequently, there was no
excess risk for ≥10 years since stopping OC use.
In the same collaborative re-analysis, data concerning the use of
progestogen-only injectable contraceptives were scanty, but the risk
pattern was comparable to that of OC. The pooled RR was 1.22, for
users for ≥5 years, but the ﬁnding was of borderline signiﬁcance, and
again there was no excess risk for ≥5 years since stopping OC use
(Appleby et al., 2007).
Therefore, long-term (i.e. ≥10 years) use of hormonal contraception
appears to increase cervical cancer in HPV-positive women. Such an
excess risk related to contraception may translate in a cumulative risk
at age 50 of 0.8% in low- and middle-income countries, and 0.4% in
high-income countries (Appleby et al., 2007; Cibula et al., 2010). The as-
sociation between OC and cervical cancer is therefore much more im-
portant in low- and middle-income countries, including selected eastern
European andLatinAmericacountries,where cervical screening in not ad-
equately utilized, and cervical cancer remains exceedingly high (Franceschi
et al., 2000; Bosetti et al., 2005, 2013). Since the riskofmortality andmor-
bidity associated with pregnancy are high in these areas of the world, the
beneﬁts of using OCs, even long term, are considered to outweigh the
risks, and there is no recommendation to limit OC use to ,10 years.
Intrauterine contraception
Intrauterine contraceptives (IUCs) belong to the most effective contra-
ceptive methods with failure rates of 0.1% and no opportunity for
imperfect use (Trussell, 2011). The highest use is still seen in China,
but IUCs of various types such as copper IUDs (Cu-IUD) or the
levonorgestrel-medicated device (LNG-IUS) have become popular in
many European countries over the past decades (Gemzell-Danielsson
et al., 2011).Apersistent barrier to IUCuse, however, is thewide-spread
belief (among both potential users and providers) of an increased risk for
PID among IUC users. Following the discovery in 1977 that the multi-
ﬁlament threads of the Dalkon Shield IUC increased the risk for PID, a
FDA subcommittee decision resulted in the recommendation that IUC
product labels should include a warning on an increased risk of PID
with IUC use (Hubacher et al., 2013). Two large studies estimated a
60% (Burkman, 1981) and, a 10-fold (Vessey et al., 1981) increased
rate of PID among IUC users compared with women using other
contraceptive methods, and the idea that the IUD caused PID was
‘conﬁrmed’. The dogma began to be questioned and in 1992 WHO
published an analysis of data from over 51 000 years of observation of
22 908 IUD users. The estimated average PID rate from these studies
was only 1.6 per 1000 women-years, but a higher risk (7 per 1000
women-years) was observed within the ﬁrst month of insertion (Farley
et al., 1992). Following this, a study randomizing women to prophylactic
antibiotic or placebo treatment prior to IUD insertion showed no differ-
ence with regard to PID between the groups (Walsh et al., 1998).
Despite evidence that PID is caused by microorganisms transferred at
sex or instrumentation of the uterus, there is still a common misunder-
standing that PID is caused by the IUC. Sexually transmitted bacteria
and non-sterile instrumentation may cause PID. However, it is also
clear that exposure to sexually transmitted bacteria not always result
in a PID. Untreated Chlamydia or gonorrhoea infection will result in
PID in ,50% of exposed women (Grimes, 2000; Mohllajee et al.,
2006). In a small but imaginative study, women were recruited to have
an IUD inserted at various intervals prior to hysterectomy (Mishell
et al., 1966). Sampleswere collected from the upper genital tract for bac-
terial cultures. The ﬁndings conﬁrmed that bacteria were present in the
uterine cavity following the IUD insertion, but cleared after the next
menses following insertion. Taken together, available data indicate that
0–5% of women with an IUD and exposed to bacteria will develop
PID (Mohllajee et al., 2006). This can usually be successfully treated
with the IUD in place.
There is evidence that the type of IUC may inﬂuence the risk of bac-
terial exposure resulting in PID. Theoretically, the gestagen inﬂuence
of the LNG-IUS on the cervical mucus may protect against intrauterine
transmission of STI agents (Gemzell-Danielsson et al., 2011), while the
copper in theCu-IUDhas a bacteriostatic effect. Thepossible protection
against transmission of pathogens as well as the reduced vaginal bleeding
associated with the LNG-IUS together with its high contraceptive efﬁcacy
may make it a suitable contraceptive method for women living with
HIV/AIDS (Heikinheimo et al., 2011). A number of demographic and
socioeconomic factors such as age, partnership, education, parity and
smoking appear to be associated with PID acquisition (Viberga et al.,
2006) The IUC–PID relationship is complex and PID diagnosis frequently
imprecise. Great care has to be taken to avoid incorrect conclusions, to
correct myths, to update guidelines, to promote effective and safe types
of IUC and to help women gain access to intrauterine contraception.
Simultaneous prevention of
unintended pregnancy and STIs
There are two approaches aimed at preventing both infection and preg-
nancy simultaneously—dual method use and the development of multi-
purpose prevention technologies (Harrison and Shields, 2010).
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Dual method use
Currently, available methods of contraception which are most effective
at preventing pregnancy do not protect against STIs, whereas condoms
which do protect against STIs are less effective at preventing pregnancy.
Promotion of condom use is often associated with relatively high preg-
nancy rates (Feldblum et al., 2007). This presents a dilemma both for
couples deciding which method to use and for healthcare providers ad-
vising them since if highly effective pregnancy prevention is required, then
dual protection involves using an effective contraceptive method to-
gether with a condom. Most individuals and couples make a choice de-
pending on their personal circumstances and priorities. For example,
mutually monogamous couples may not be at risk of STIs, while
women not in a committed relationship and those who have sex with
men who have other partners may be more concerned about the risk
of infection than of pregnancy. In most high-income countries, dual
method use is infrequent 7% in a study of young women in California
(Raine et al., 2003), 14% among Australian women aged 25–30 (Lucke
et al., 2009). In countries in sub-SaharanAfricawhereHIV/AIDs and un-
intended pregnancy are both common, use of dual protection is similarly
low. In a nationally representative survey of young South African women
aged 15–24, only 7% of current contraceptive users reported using dual
methods (MacPhail et al., 2007). In the HBSC survey of 15-year-old girls
in Europe, theuseof dual protection ranged from31% in theNetherlands
to just 3.5% in Greece and 2.6% in Estonia (Godeau et al., 2008).
Simultaneous protection against STI and
unwanted conception
For couples at known risk of STI, including HIV, products which provide
simultaneous protection against infection and unintended pregnancy
may be more acceptable among stable couples than products that only
protect against infection. There ismuchenthusiasm for developingmulti-
purpose technologies. One approach is to combine a known contracep-
tive with a known microbicide or virucide. Research is underway on a
vaginal gel containing LNG and a microbicide (Carraguard) for either
emergency or continuous contraception (Brache et al., 2007). Barrier
methodsof contraception that includesmale and female condomsordia-
phragms could be impregnated with anti-infective agents. Recognizing
the problems with consistent and correct use of barrier methods,
there is considerable interest in using long-acting delivery systems such
as contraceptive vaginal rings or intrauterine systems releasing microbi-
cides. Multipurpose vaccines are also in development and the discovery
of potentially suitable antigens for several STI pathogens is progressing,
including Chlamydia, HIV, HSV, gonorrhoea and trichomonas (Harrison
and Shields, 2010).
Conclusions and
recommendations
STIs and unintended pregnancies are common everywhere and present
major public health problems. Action can be taken better to understand
the epidemiology and to identify opportunities for improved prevention
strategies (Table IV).
Data are frustratingly scarce or unreliable. Surveys of sexual behaviour
are more systematically undertaken in developing countries than else-
where, but all rely on self-reporting and the results are difﬁcult to
compare. With regard to unintended pregnancy, robust reporting
systems for induced abortion are lacking even in countries where abor-
tion is legal; and data on unintended pregnancy ending in childbirth are
very rare. Efforts to increase contraceptive use and reduce unintended
pregnancy, as reﬂected by rates of induced abortion, have resulted in
decreased TFRs worldwide and increased contraceptive prevalence.
Yet abortion rates are still worryingly high and up to one-third of preg-
nancies ending in childbirth may be unplanned. In the developing
world, preventingunintendedpregnancywould goa longway to reducing
maternal mortality and morbidity.
National rates of STIs are similarly hard to come by and estimates are
usually calculated from laboratory data or STI clinic attendances, both de-
pending on symptomatic men and women attending for treatment. For
some infections, there appears tobenodatacollection.Betterdatacollec-
tion including population-based estimates from surveys such as Natsal
(Sonnenberg et al., 2013) would help in the design of interventions to de-
crease unsafe sex and to screen and treat for infection.While routine na-
tional screening for STIs may seem desirable, lessons can and should be
learned from the trials of national STI screening programmes (for
C. trachomatis) which have served to highlight how little we know about
the natural history of this common infection. Gains are also being made
in respect of vaccination against HPV and lessons could be learned from
this programme when, and if, vaccines for other STIs become available.
Barrier methods of contraception—particularly the male condom—
are effective at protecting against both pregnancy and STIs, but correct
and consistent use is challenging, particularly for young people, and
dual method use seems unlikely ever to become common. The more
(and most) effective methods of contraception do not protect against
STIs and some may even increase the risk of acquisition or persistence
of infection with, in some cases, serious consequences. Nevertheless,
the balance of risk is in favour of use of effective contraception since,
even in Europe, unintended pregnancy can have major social and
health consequences. New developments in multipurpose technologies
aimed at producing a single device or drug which prevents infection and
pregnancy simultaneously are highly desirable particularly if they can be
made long acting—but they are a long way off.
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Table IV Actions to improve understanding of sexual
ill-health and opportunities for prevention.
Standardized collection of data on induced abortion.
National surveys on unintended births.
Population-based surveys testing for common STIs and sexual behaviour.
Critical evaluation of national STI screening trials.
Health policy changes suggested by the study of HPV vaccination
programmes.
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Ameeting was organized by the ESHRE (30–31 August 2013) to discuss
the above subjects. The contributors included: J.L.H. Evers (Department
of Obstetrics and Gynecology, Maastricht University Medical Centre,
Maastricht, the Netherlands), T. Farley (Sigma3 Services SARL Scientiﬁc
& Statistical Solutions, Nyon, Switzerland), K. Gemzell-Danielsson
(Chair Division of Obstetrics and Gynecology, Department of
Women’s and Children’s Health Karolinska Institutet, Karolinska Uni-
versityHospital, Stockholm, Sweden),A.Glasier (Centre forReproduct-
ive Biology, University of Edinburgh, UK), P. Hannaford (NHSGrampian
Chair of PrimaryCare and Vice Principal of Research and Knowledge Ex-
change, Academic Primary Care, Division of Applied Health Sciences,
University of Aberdeen, Foresterhill Health Centre, Aberdeen, UK;
P. Hannaford prepared the abstract and the slides presented in his
absence by A. Glasier. P. Hannaford contributed also to the preparation
of the ﬁnal manuscript), C. La Vecchia (Istituto di Ricerche Farmacolo-
giche ‘MarioNegri’ andDepartment ofClinical Sciences andCommunity
Health, Universita` degli Studi di Milano, Milano, Italy), C. Moreau (Popu-
lation Family and Reproductive Health, Bloomberg School of Public
Health, Hopkins University, Baltimore, MD, USA and INSERM U1018,
CESP-‘Gender, Sexual and Reproductive Health’, Hopital du Kremlin
Bicetre, Le Kremlin Bicetre, France) and J. Stephenson (Margaret Pyke
Professor of Sexual & Reproductive Health, UCL, Programme Director
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for Women’s Health, UCL Partners, Research Department of Repro-
ductive Health, Institute of Women’s Health, University College
London, London, UK). The discussants included: D.T. Baird (Centre
for Reproductive Biology, University of Edinburgh, UK), P.G. Crosignani
(Scientiﬁc Direction, IRCCS Ca’ Granda Foundation, Maggiore Policli-
nico Hospital, Milano, Italy) and L. Gianaroli (SISMER, Reproductive
Medicine Unit, Bologna, Italy). The report was prepared by A. Glasier
and P.G. Crosignani.
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